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Abstract
A recombinant plasmid that co-expressed ubiquitin and porcine circovirus type 2 (PCV2) virus capsid protein (Cap),
denoted as pc-Ub-Cap, and a plasmid encoding PCV2 virus Cap alone, denoted as pc-Cap, were transfected into
293T cells. Indirect immunofluorescence (IIF) and confocal microscopy were performed to measure the cellular
expression of Cap. Three groups of mice were then vaccinated once every three weeks for a total of three doses
with pc-Ub-Cap, pc-Cap or the empty vector pCAGGS, followed by challenging all mice intraperitoneally with 0.5
mL 10
6.5 TCID50/mL PCV2. To characterize the protective immune response against PCV2 infection in mice, assays
of antibody titer (including different IgG isotypes), flow cytometric analysis (FCM), lymphocyte proliferation,
cytokine production and viremia were evaluated. The results showed that pc-Ub-Cap and pc-Cap were efficiently
expressed in 293T cells. However, pc-Ub-Cap-vaccinated animals had a significantly higher level of Cap-specific
antibody and induced a stronger Th1 type cellular immune response than did pc-Cap-vaccinated animals,
suggesting that ubiquitin conjugation improved both the cellular and humoral immune responses. Additionally,
viral replication in blood was lower in the pc-Ub-Cap-vaccinated group than in the pc-Cap and empty vector
groups, suggesting that the protective immunity induced by pc-Ub-Cap is superior to that induced by pc-Cap.
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1. Background
Porcine circovirus type 2 (PCV2) is a small, non-envel-
oped, single-stranded, circular DNA virus with a 1767
nt or 1768 nt ambisense genome [1] that contains at
least two major open reading frames (ORFs). ORF1
encodes the replication proteins (Rep and Rep’) involved
in virus replication and ORF2 encodes the capsid pro-
tein (Cap) [2,3]. Cap, a protein associated with the
development of neutralizing antibodies and antibody
protection [4,5], has been a leading target for designing
new vaccines against PCV2 infection.
Immunologic potential of a DNA vaccine encoding the
PCV2 Cap in mice was first investigated by Kamstrup, et
al. [6]. DNA vaccines may be capable of inducing immu-
nity regardless of maternally derived antibodies [7-9]
and they have induced protective cellular and humoral
immunity in preclinical models of infectious diseases.
However, DNA vaccine applications are limited due to
problems related to delivery, species of the immunized
animals and degradation of plasmid DNA [10], result-
ing in modest cellular and humoral immune responses
[11]. To compensate for these limitations, numerous
studies have explored methods to improve immune
responses induced by DNA immunization by optimiz-
ing plasmid design, vaccine delivery systems and adju-
vants [12]. Adjuvants are of particular interest because
they may enhance DNA delivery and increase the mag-
nitude and duration of plasmid DNA expression [13].
Molecular adjuvants, such as co-stimulatory chemo-
kines and cytokines, have been used previously in con-
junction with DNA vaccines and have served as
immune modulators [14].
Ubiquitin, a 76-amino-acid peptide found in the cyto-
plasm of eukaryotic cells, is normally involved in con-
trolling intracellular protein turnover [15] and was
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antigens in the adjuvant setting. Ubiquitinated proteins
targeted to the proteasome system [16] are processed
and presented through the major histocompatibility
complex (MHC) class I pathway to stimulate differentia-
tion and clonal expansion of MHC class I-restricted T
cells, which are typically CD8
+, cytotoxic T cells [17-19].
This strategy enhances proteasome-dependent degrada-
tion of endogenously synthesized antigens and results in
an increased cell-mediated response against the conju-
gated antigen in vivo [20-22]. Tuberculosis and influ-
enza virus [23,24] DNA vaccines using ubiquitin to
enhance the immune response showed better results
compared to DNA vaccine alone.
In this study, BALB/c mice were vaccinated with pc-
Ub-Cap and pc-Cap to investigate whether ubiquitin
conjugation to ORF2 would enhance the immune
response. In addition, pc-Ub-Cap vaccination was com-
pared with pc-Cap vaccination to assess if pc-Ub-Cap
provided better protection against PCV2. The results
demonstrated that ubiquitin conjugation improved both
the cellular and humoral immune responses in PCV2
DNA vaccinated animals and that the protective immu-
nity induced by pc-Ub-Cap is superior to that induced
by pc-Cap.
2. Methods
2.1 Virus, cells, mice and plasmids
The virulent PCV2 isolate, 871 (no. EU420015), was ori-
ginally isolated from pigs with naturally occurring post-
weaning multisystemic wasting syndrome (PMWS) and
serially passaged 32 times in PK-15 cells. 293T cells
used for transfection were maintained at Harbin Veter-
inary Research Institute of China and grown in minimal
essential medium (Gibco) supplemented with penicillin,
streptomycin and 10% heat-inactivated fetal bovine
serum (FBS; Gibco). Eight-week-old female BALB/c
mice were purchased from Harbin Veterinary Research
Institute of Chinese Academy of Agricultural Science
and raised in automatic, extrusion-independent venting
isolation cages. Animal maintenance and experimental
p r o t o c o l sw e r ea p p r o v e db yt h eA n i m a lE x p e r i m e n t
Ethics Committee of the authors’ institute.
The recombinant plasmids, pMD18-T-ORF2 and
pMD18-T-ubiquitin, were generated using ORF2 and
ubiquitin fragments inserted into pMD18-T and main-
tained at Harbin Veterinary Research Institute of China.
The ORF2 gene coding wild-type Cap was amplified
from the total DNA of PCV2 by polymerase chain reac-
tion (PCR). The ubiquitin gene was synthesized based
on the pig ubiquitin amino acid sequence with Gly76
changed to Arg76 (no. M18159). The Kozak sequence,
GCCACC, served as the upstream start codon for both
fragments.
2.2. Construction of the eukaryotic expression plasmids
All expression plasmids were constructed using
pCAGGS (a eukaryotic expression vector kindly pro-
vided by Dr. Zhigao Bu of the Harbin Veterinary
Research Institute) as a vector. Primers used for PCR
amplification are listed in Table 1. The entire ORF2 was
amplified from the recombinant plasmid pMD18-T-
ORF2 using the primer pair FW/RV. The PCR product
digested with Xho I, Bgl II was subcloned into the mam-
malian expression vector, pCAGGS (Promega), to con-
struct the recombinant expression plasmid, pc-Cap. To
generate the coexpression plasmid, a 790 bp DNA frag-
ment with a linker encoding the full length Cap protein
and a 270 bp DNA fragment with a linker encoding the
ubiquitin gene, were amplified by PCR using primer
pairs fw1/rv1 and fw2/rv2, respectively. The PCR pro-
ducts were used as a template to construct the Ub-Cap
fusion gene. This fusion genew a sg e n e r a t e db yl i n k i n g
ORF2 downstream of ubiquitin and was amplified using
the fw1/rv2 primer pair. The PCR product was digested
with Sac I, Xho I and subcloned into the expression vec-
tor, pCAGGS, to construct the recombinant expression
plasmid, pc-Ub-Cap. Finally, the plasmids were purified
using an EndoFree Plasmid Giga kit column (Qiagen)
for use as a DNA vaccine.
2.3. IIF and confocal microscopy
At 48 h post-transfection, 293T cell were fixed with
absolute methanol for 5 min and processed for an IIF
assay using a monoclonal antibody (mAb) against the
Cap protein of PCV2 (1:200) [25], followed by applica-
tion of FITC-conjugated, goat-anti-mouse IgG (1:100)
(Sigma). Fluorescent images were examined under an
inverted fluorescence microscope (Olympus IX70).
Forty-eight hours post-transfection, cells were fixed
using 4% paraformaldehyde for 20 min at room tem-
perature and then incubated separately with PCV2 Cap-
specific mAb (1:100) and FITC-conjugated, goat-anti-
mouse IgG (1:64). After washing with PBS-T (1×PBS,
0.5% Tween 20), the cells were stained with 100 μg/mL
PI for 15 min at room temperature. The cells were
washed three times with PBS-T and then analyzed with
a Leica confocal microscope using the Leica confocal
software (TCS SP5 version).
2.4. In vivo immunization and challenge
Seventy-five mice were randomized into three groups of
25 mice each. Two groups of 25 mice were immunized
with pc-Cap and pc-Ub-Cap, respectively, and the third
group of twenty-five mice was immunized with the
empty vector, pCAGGS. For immunization, 100 μgo f
plasmid DNA was injected into the quadriceps femoris
muscles once every three weeks for a total of three doses.
Serum samples for Enzyme-Linked Immunosorbent
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every two weeks after immunization until the end of the
experiment. Six weeks after the final injection, five mice
from each group were euthanized and tissues were har-
vested for flow cytometric analysis (FCM), lymphocyte
proliferation assays and cytokine assays by ELISA, includ-
ing IFN-g and IL-2. At 18 weeks p.i., the remaining
twenty mice from each group were challenged intraperi-
toneally with 0.5 mL PCV2 inoculum (10
6.5 TCID50/mL).
Five mice from each group were euthanized at two, four,
six and eight weeks p.c., and whole blood was collected
for quantification of the PCV2 viral load by real-time
PCR as described previously [26].
2.5. Detection of Cap-specific IgG, IgG1 and IgG2a
antibodies
An endpoint ELISA was performed to assess the titers
of total IgG, IgG1 and IgG2a antibodies against PCV2
Cap protein. The recombinant Cap protein with deleted
nuclear localization signal (deletion of the 41, N-term-
inal amino acid residues was used as the coating antigen
[27]. Briefly, 96-well plates (Jet) were coated overnight
at 4°C with 0.1 mL of purified recombinant antigen (5
mg/mL) in a coating solution (bicarbonate buffer, pH
9.6). The plates were then blocked with 5% skim milk
and serum samples were applied in 0.1 mL of serial
two-fold dilutions, starting with a 1:64 dilution. The
plates were then incubated at 37°C for 40 min. The
bound antibodies were detected by horseradish peroxi-
dase-conjugated goat anti-mouse IgG, IgG1 or IgG2a
antibody (diluted 1:6,000; Southern Biotechnology
Associates). The substrate, 3, 3-, 5-, 5-tetramethylbenzi-
dine (TMB Sigma) was used to visualize the reaction.
The results were expressed as the ratio of OD450 pro-
duced by the serum samples compared with negative
control serum. Ratio values higher than 2.1 were consid-
ered to be positive for antibody, and antibody titers were
then defined as the reciprocal of the highest dilution of
sample for which the ratio value was higher than 2.1.
The datas are presented as the log2 value of each titer.
2.6. Lymphocyte proliferation assay
Six weeks after the final injection, splenocytes were isolated
as described previously by Kang, et al. [28]. Splenocytes
were cultured in RPMI-1640 with 10% FBS containing
penicillin (100 units/ml) and streptomycin (100 units/mL)
in triplicate at a density of 1 × 10
5 cells/well (100 μl total
volume) in 96-well plates. The cultures were stimulated for
18 h with either 20 μl1 0
6.5 TCID50/mL inactivated PCV2
as the specific antigen or with no antigen as a negative con-
trol. After incubation at 37°C in 5% CO2 for 96 h, 20 μlo f
Cell Counting Kit-8 (Beyotime Biotech Co., Ltd) was added
to each well and the cells were incubated for 1 h. At the
end of the incubation, the plates were measured at 450
nm. The stimulation index (SI) was calculated as the ratio
of the average OD value of wells containing antigen-stimu-
lated cells to the average OD value of wells containing cells
cultured with medium alone.
2.7. Flow cytometric analysis (FCM)
Flow cytometric analysis was performed to determine
the percentage of CD4+T and CD8+T cells. All condi-
tions were repeated in triplicate. Splenocytes (10
6 cells)
were stimulated for 18 h with 20 μlo f1 0
6.5 TCID50/mL
inactivated PCV2 as the specific antigen or with no anti-
gen as a negative control. After culturing for 18 h at 37°
C, splenocytes were resuspended in 25 μl PBS and incu-
bated with the following antibodies at a concentration
of 0.075 μg, 0.05 μga n d0 . 1μgp e r1 0
6 cells: 25 μl
diluted (1:200), FITC-conjugated, anti-mouse CD4
(L3T4; BD Biosciences); Percp-conjugated anti-mouse
CD3 (CD3ε chain; BD Biosciences) mAb; and PE-conju-
gated anti-mouse CD8a (Ly-2; BD Biosciences) mAb.
After 30 min incubation, the cells were washed and ana-
lyzed with a FACS Calibur cytometer using CellQuest
software (BD Biosciences). A minimum of 10
4 cells were
analyzed for each sample.
2.8. Cytokine assay
Culture supernatants of lymphocyte were removed asepti-
cally from 96 wells after incubation, as in the lymphocyte
Table 1 Oligonucleotide primers used in this study
Gene Primers Sequences of primers(5’®3’) Length Anneal tem
ORF2 Fw AATCTCGAGGCCACCATGACGTATCCAAGG 717 bp 56°C
Rv ATTAGATCTTTATTCATTAAGGGTTAAGTG
ub-linker fw1 gga gagctcgccaccatgcagatcttcgtg 270 bp 56°C
rv1 gccgccgccgctgccgccgccgccgctgccgccgccgcctcttcccctcaagcg
linker-ORF2 fw2 ggcggcggcggcagcggcggcggcggcagcggcggcggcATGACGTATCCAAGG 790 bp 56°C
rv2 ctcgag TTATTCATTAAGGGTTAAGTGGGGGG
U-ORF2 fw1 gga gagctc gccaccatgcagatcttcgtg 1030 bp 56°C
rv2 ctcgag TTATTCATTAAGGGTTAAGTGGGGGG
Note: Italic denotes restriction enzyme site; underline denotes linker; TTA denotes stop.
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in the culture supernatants of splenocytes by ELISA kit
(Beijing 4A Biotech Co., Ltd) according to manufacturer
instructions. The cytokine assay was performed as follows:
100 μL diluted standard or sample was added to each well,
followed by 50 μl biotin-conjugated anti-cytokine anti-
body. The plate was covered with aluminum foil and incu-
bated for 120 min at room temperature. The plate was
then washed four times with 350 μl of wash buffer, and
100 μl of enzyme conjugate working solution was added
to each well and allowed to incubate at room temperature
for 30 min. The plate was washed four more times, and
100 μl of chromogenic substrate was incubated in each
well for 20 min at room temperature to develop the colori-
metric reaction. Color development was stopped with 100
μL stop buffer. The plate was read immediately at 450 nm
on the Universal Microplate Reader ELx800 (Bio-Tek
Instruments, Inc., Winooski, VT, USA). A standard curve
for each cytokine was obtained using the standard protein
provided by the manufacturer.
2.9. Quantitative real-time PCR for evaluation of viremia
At two, four, six and eight weeks p.c., DNA was
extracted from 500 μl of whole blood by using the
DNeasy Blood & Tissue kit (Qiagen, Chatsworth, CA,
USA). Viral DNA levels in samples collected after PCV2
c h a l l e n g ew e r ed e t e r m i n e du s i n gaq u a n t i t a t i v e ,r e a l -
time PCR as described previously [26]. A forward (5’-
ATTAGTCTTCCAATCACGCTTCTG-3’) and a reverse
(5’-CTTGTTGGAGAGCGGGAGTC-3’)p r i m e rw e r e
used to amplify a 135 bp fragment from the ORF2 of
PCV2. SYBR real-time PCR was performed using the
BIO-RAD iQ5 (Corbett, Sydney, Australia) and 12.5 μL
of SYBR
® Premix Ex Taq™ (Perfect Real Time, TaKaRa,
Dalian, China) was used in each reaction. Serial dilu-
tions of plasmid pORF2 were used to obtain a standard
curve. The numbers of virus copies for each sample is
presented as the mean value of duplicate reactions. The
detection limit of this assay was 10
2 copies/mL.
2.10. Statistical analysis
One-way analysis of variance (ANOVA) was used to
determine statistical differences in humoral and cellular
immune responses between groups. Differences where p
< 0.05 were considered significant. Statistical analysis
was performed using SPSS version 12.0 (SPSS) and Sta-
tistical Analysis System (SAS) for windows 6.12 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. Expression levels of recombinant plasmids
To investigate whether the Cap protein is expressed
in 293T cells transfected with pc-Cap and pc-Ub-Cap,
IIF and confocal microscopy were performed at 48 h
post-transfection. The IIF assay showed that 293T cells
transfected with pc-Cap and pc-Ub-Cap were recognized
b ym A bt oC a pa t4 8hp o s t - t r a n s f e c t i o n ,w h i l et h e
pCAGGS infected 293T cells were not recognized by the
specific mAb (Figure 1A). Confocal microscopy analysis
showed that the expressed Cap protein was localized in
the nuclei of cells (Figure 1B).
3.2. Total IgG and isotypes of serum antibody against
PCV2 Cap protein
To evaluate for seroconversion of the mice, an indirect
ELISA was performed to detect PCV2 Cap protein spe-
cific antibodies. As shown in Figure 2, the titers for total
IgG against PCV2 Cap protein in the pc-Ub-Cap group
seroconverted at two weeks post immunization (p.i.),
while those in the pc-Cap vaccine groups seroconverted
at four weeks p.i. Four weeks after primary immuniza-
tion, the antibody titer reached a detectable level in all
vaccinated groups except for the group immunized with
the vector. A further increase in antibody levels was
o b s e r v e da ts i xw e e k sa f t e rp r imary immunization. The
pc-Ub-Cap protocol induced higher IgG titers with
peaks of 13.2 ± 0.837 log2 at 12 weeks p.i. compared
with titers from the pc-Cap (10.2 ± 0.837 log2) vaccines
after the same amount of time. This difference was sta-
tistically significant at eight weeks (P <0 . 0 5 ) ,1 0w e e k s
and 12 weeks (P < 0.01) after primary immunization.
Anti-Cap antibodies developed earlier and with higher
titers in the pc-Ub-Cap compared to the pc-Cap-immu-
nized group. After challenge, the antibody levels in both
vaccine groups increased sharply compared to the con-
trol group, though the antibody values with pc-Ub-Cap
were remarkably higher than with pc-Cap. Throughout
the testing period, Cap antibody levels in pc-Ub-Cap-
immunized mice were higher than in the pc-Cap-immu-
nized mice.
We evaluated the IgG1/IgG2a isotypes against PCV2
Cap protein to determine the antibody response profile
induced by pc-Cap and pc-Ub-Cap. Both pc-Cap and
pc-Ub-Cap immunized mice had significantly higher
levels of IgG2a than IgG1. The pc-Cap plasmid stimu-
lated significantly higher IgG2a antibodies than IgG1
from 12 to 18 weeks p.i. (P < 0.01), with a peak IgG2a
titer of 12.4 ± 1.517 log2 at 14 weeks (Figure 3b). Simi-
larly, the pc-Ub-Cap plasmid stimulated significantly
higher IgG2a antibodies than IgG1 from 2 to 18 weeks
p.i. (two to four weeks p.i. P < 0.01; six to ten weeks
a n d1 4t o1 8w e e k sp . i . ,P<0 . 0 5 ) ,w i t hap e a kI g G 2 a
titer of 13.2 ± 1.483 log2 at 14 weeks (Figure 3c). Strik-
ingly, mice immunized with pc-Cap and pc-Ub-Cap pro-
duced detectable levels of Cap-specific IgG2a antibodies.
Though both pc-Ub-Cap and pc-Cap resulting in high
IgG2a levels, immunization with pc-Ub-Cap DNA vac-
cine did still result in significantly higher level of IgG2a
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from two to eight weeks p.i. (p < 0.01).
3.3. Enhanced T cell proliferation in response to pc-Ub-
Cap
To measure the T cell proliferative response, splenocytes
from mice were isolated and restimulated in vitro with
inactivated PCV2 six weeks after the last immunization.
A ss h o w ni nT a b l e2m i c ei m m u n i z e dw i t hp c - U b - C a p
had strong stimulation of lymphocytes sensitized PCV2
and reached the highest proliferative activity compared
to mice immunized with the vector. Notably, both pc-
Cap and pc-Ub-Cap elicited a proliferative response that
was absent in mice administered the vector alone. How-
ever, splenocytes from mice immunized with pc-Ub-Cap
induced significantly stronger T cell proliferation
Figure 1 Expression of the Cap protein in vitro. (A) Indirect immunofluorescence detection of Cap on 293T cells. 293T cells were previously
transfected with 1 μg of different recombinant plasmids or the empty vector, in a 12-well plate. Forty-eight hours post-transfection, cells were
fixed with cold acetone, treated with anti-Cap monoclonal antibody (mAb), and stained with FITC conjugated secondary antibody. Green: Cap
protein-positive 293T cells; dark: negative cells. A was transfected with pc-Cap, B with pc-Ub-Cap and C with vector. (B) 293T cells were
transiently transfected with pc-Cap and pc-Ub-Cap. 48 h post transfection cells were fixed and the distribution of recombinant proteins was
analyzed by confocal microscopy. Localization of recombinant product in 293T cells. (A and D) Incubated with of PCV2 Cap specific mAb
followed by incubation with a secondary antibody conjugated with FITC. (B and E) staining of the nucleic lamina with PI. (C and F) Merge of A
and B, D and E. Green channel (left pannel), red channel (middle pannel) and merge (right pannel). The bar represents 7.5 μm.
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immunized with pc-Cap. The pc-Ub-Cap plasmid eli-
cited significantly higher cell proliferation than the pc-
Cap (p < 0.05).
3.4. Cap-induced cellular immune responses
The proportion of CD4
+ T cells and CD8
+ T cells in the
stimulated splenocytes were determined by FCM. As
shown in Table 2 significant upregulation of CD4
+ T
cells and CD8
+ T cells was elicited in all of the vaccine
groups compared with the control group (P < 0.05).
With regard to the expression of CD4
+ T cells and CD8
+ T cells, the pc-Ub-Cap group showed significant
increases (P < 0.05) when compared with the pc-Cap
group.
3.5. Ub-Cap constructs promote Th1 type cellular immune
responses
To profile the cytokine levels induced by the DNA plas-
mids, an ELISA kit was used to measured levels of the
Th1 cytokines, IFN-g and IL-2, secreted by splenic lym-
phocyte cells six weeks after the last immunization. As
depicted in Figure 4, the highest level of interferon-
gamma (IFN-g) and interleukin-2 (IL-2) was induced in
the pc-Ub-Cap-immunized group, followed by the pc-
Cap and vector-immunized groups.
3.6. Viremia after challenge
PCV2 DNA was detected by real-time PCR based on
sequence coding for nucleocapsid protein from blood
samples of PCV2 challenged mice. The occurrence of
viremia and the mean number of PCV2 genomic copies
are presented in Table 3. At weeks two, four, six and
eight post challenge (p.c.), the viral load in the blood of
mice immunized with DNA pla s m i d sw a sl e s st h a ni n
mice immunized with the empty vector. Specifically, the
highest level of PCV2 DNA was observed in the vector-
immunized group, followed by the pc-Cap and pc-Ub-
Cap-immunized groups. The pc-Ub-Cap-immunized
group exhibited a reduction in the level of viremia with
a significantly decreased number of PCV2 genomic
copies at four time points above (P < 0.05).
4. Discussion
Previous studies reported that Cap protein induces pro-
tection against subsequent challenge with PCV2 and
that ORF2 plasmid DNA vaccines [12,29-31] were more
efficacious than Cap protein-based vaccines [12]. Addi-
tionally, two reports have shown that Ub-antigen conju-
gation can target endogenously synthesized antigenic
proteins for rapid degradation and improve their antige-
nicity and immunogenicity [22,32]. Based on these
reports, the pc-Ub-Cap was constructed and its ability
to protect against PCV2 is promising.
To explore a more ideal DNA vaccine and enhance
cell-mediated immune responses, we constructed a
recombinant plasmid co-expressing swine ubiquitin and
a Cap-encoding gene from PCV2. A Kozak consensus
sequence was introduced upstream of ubiquitin, which
is crucial for the efficient initiation of translation [33].
We mutated the C-terminal glycine residue of Ub to
arginine as previous reported [34], because it is essential
for a DNA vaccine to induce antigen-specific CD8+ T
cells based on the Ub fusion degradation pathway.
Figure 2 Kinetics of total IgG production against PCV2 Cap protein at various times p.i. The results are shown as means ± SD (n = 5).
Significant differences between the vaccines are indicated: **, P < 0.01; *, P < 0.05.
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ated after restimulation in vitro with inactivated PCV2.
Enhanced cell-mediated immune responses were observed
in mice immunized with pc-Ub-Cap. In the present study,
we investigated the Cap-specific lymphoproliferative activ-
ity, splenocyte phenotypes and levels of the Th1 cytokines,
IFN-g and IL-2, secreted by splenic lymphocytes induced
by PCV2. The results demonstrated that the ubiquitin-
fused DNA was more efficient in eliciting lymphoprolifera-
tive responses in CD4
+ T cells and CD8
+ T cells than the
pc-Cap plasmid. Moreover, we found that the ubiquitin-
fused antigen induced antigen-specific CD8
+ T cells based
on the Ub fusion degradation pathway.
Th1 cells, which produce IL-2 and IFN-g, induce the
activation of macrophages, delayed-type hypersensitivity
and the production of IgG2a [35,36]. When the immune
profiles of mice at the stage of p. i. were explored, the
Th1-associated cytokines (IFN-g and IL-2) were
expressed more by splenocytes from mice receiving
DNA vaccines. Furthermore, in vivo studies showed that
immunization with DNA plasmids induced greater
IgG2a antibody production compared to IgG1, suggest-
ing a stronger Th1 pattern of immune response. In our
model, the pc-Ub-Cap-immunized mice exhibited higher
levels Th1-based immune responses compared to the
pc-Cap-vaccinated mice.
The IgG2a antibody is reportedly important in pro-
tecting against PCV2 infection [12]. This notion was
confirmed by the viremia results from blood samples by
quantitative, real-time PCR. Viremia was monitored at
two, four, six and eight weeks p.c. by quantitative, real-
time PCR. The results revealed that the viral loads in all
Figure 3 Cap-specific IgG isotypes induced in the pc-Cap(b)
and pc-Ub-Cap(c), and control (a)groups. The results are shown
as means ± SD (n = 5). The letters ‘a’ and ‘b’ above columns
indicate significantly higher IgG isotype with values of P < 0.05 and
P < 0.01, respectively, at the same time in a group. Mice were
challenged at 18 weeks p.i.
Table 2 PCV2 Cap-specific lymphoroliferative response
and FCM analysis of mice splenocytes
Group SI stimulation of inactivated PCV2(mean
mice splenocytes ± SD)
CD4
+ cells(%) CD8
+ cells(%)
Vector 1.00 ± 0.00
c 9.42 ± 0.75
c 4.34 ± 0.28
c
pc-Cap 1.29 ± 0.107
b 16.6 ± 1.35
b 5.33 ± 0.23
b
pc-Ub-Cap 1.73 ± 0.098
a 23.02 ± 1.98
a 7.47 ± 0.36
a
Shared letters above columns indicate no significant difference (P > 0.05),
whilst different letters indicate significant differences among the groups (P <
0.05) (n = 5).
Figure 4 Cytokine profile of proliferation T cells.T h e
splenocytes were re-stimulated with inactivated PCV2. The
supernatants were collected. IFN-r and IL-2 concentration (ng/mL)
were determined by ELISA.
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ental vector control, particularly at weeks eight p.c. At
this time point, a high viremia was observed in the
blood of the empty vector control group compared with
a decreasing viremia in the blood of vaccinated animals.
The viremia observed in each group was consistent with
the total antibody response results by indirect ELISA
assay, which demonstratedt h a tm i c ei m m u n i z e dw i t h
pc-Ub-Cap developed significantly higher Cap-specific
antibody titers than those inoculated with pc-Cap.
Other reports showed that the total antibody response
in PCV2 followed the NA titers in subclinically infected
pigs, with seroconversion occurring from 15 dpi
onwards [37,38]. Our results also suggest that the ten-
dency of antibody to protect against PCV2 infection
coincided with decrease of virus load.
5. Conclusions
In summary, we have characterized the immune
response against PCV2 provided by the pc-Cap and the
pc-Ub-Cap DNA vaccines in mice. In the present study,
ubiquitin-tagging of the Cap antigen enhanced the Th1
profile of cellular immune response. In addition, a DNA
plasmid fused with ubiquitin elicited a more robust
humoral immune response than the plasmid without
ubiquitin, suggesting that ubiquitin-fusion of an immu-
nogen can improve its immunogenicity.
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